Ser318
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser318  -  HuR (human)

Site Information
GDkILQVsFkTNkSH   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 2246702

In vivo Characterization
Methods used to characterize site in vivo:
electrophoretic mobility shift ( 4 ) , immunoassay ( 6 ) , immunoprecipitation ( 6 , 7 ) , mass spectrometry ( 1 , 5 ) , mutation of modification site ( 2 , 3 , 4 , 6 , 8 , 9 ) , phospho-antibody ( 7 , 8 , 9 ) , western blotting ( 3 , 4 , 6 , 7 , 8 )
Disease tissue studied:
breast cancer ( 3 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , colorectal cancer ( 7 ) , colorectal carcinoma ( 7 ) , prostate cancer ( 6 )
Relevant cell line - cell type - tissue:
breast ( 1 ) , CCD 841 ( 7 ) , colon ( 7 ) , DLD1 (intestinal) ( 7 ) , E.coli (bacterial) ( 4 ) , HMC-1 ( 8 ) , Jurkat (T lymphocyte) ( 5 ) , LNCaP (prostate cell) ( 6 ) , MCF-7 (breast cell) ( 3 ) , mesangial ( 4 , 9 )

Upstream Regulation
Putative in vivo kinases:
PKCA (human) ( 6 ) , PKCD (human) ( 3 , 7 , 8 , 9 )
Kinases, in vitro:
PKCD (human) ( 9 )
Treatments:
adriamycin ( 3 ) , angiotensin_2 ( 8 , 9 ) , rottlerin ( 7 ) , siRNA ( 3 , 6 )

Downstream Regulation
Effects of modification on HuR:
intracellular localization ( 6 , 9 ) , molecular association, regulation ( 2 , 3 , 4 , 7 , 8 ) , protein degradation ( 6 )
Effects of modification on biological processes:
apoptosis, induced ( 3 ) , carcinogenesis, altered ( 7 ) , cell cycle regulation ( 7 ) , cell motility, altered ( 7 , 8 )
Induce interaction with:
14-3-3 theta (human) ( 8 ) , RNA ( 3 , 4 , 7 )
Inhibit interaction with:
RNA ( 2 )

Disease / Diagnostics Relevance
Relevant diseases:
colorectal carcinoma ( 7 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Scheiba RM, et al. (2014) The C-terminal RNA binding motif of HuR is a multi-functional domain leading to HuR oligomerization and binding to U-rich RNA targets. RNA Biol 11, 1250-61
25584704   Curated Info

3

Latorre E, et al. (2014) Loss of protein kinase Cδ/HuR interaction is necessary to doxorubicin resistance in breast cancer cell lines. J Pharmacol Exp Ther 349, 99-106
24492650   Curated Info

4

Schulz S, et al. (2013) Domain-specific phosphomimetic mutation allows dissection of different protein kinase C (PKC) isotype-triggered activities of the RNA binding protein HuR. Cell Signal 25, 2485-95
23978401   Curated Info

5

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

6

Chu PC, Chuang HC, Kulp SK, Chen CS (2012) The mRNA-stabilizing factor HuR protein is targeted by β-TrCP protein for degradation in response to glycolysis inhibition. J Biol Chem 287, 43639-50
23115237   Curated Info

7

Doller A, et al. (2011) High-constitutive HuR phosphorylation at Ser 318 by PKC{delta} propagates tumor relevant functions in colon carcinoma cells. Carcinogenesis 32, 676-85
21310943   Curated Info

8

Doller A, et al. (2010) Tandem phosphorylation of serines 221 and 318 by protein kinase Cdelta coordinates mRNA binding and nucleocytoplasmic shuttling of HuR. Mol Cell Biol 30, 1397-410
20086103   Curated Info

9

Doller A, et al. (2008) Posttranslational modification of the AU-rich element binding protein HuR by protein kinase Cdelta elicits angiotensin II-induced stabilization and nuclear export of cyclooxygenase 2 mRNA. Mol Cell Biol 28, 2608-25
18285462   Curated Info